We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » PFIZER'S COMBO DRUG LEADS LIFE CYCLE EXTENSION TREND
PFIZER'S COMBO DRUG LEADS LIFE CYCLE EXTENSION TREND
February 6, 2004
In a financially strategic move, Pfizer is expected this spring to introduce a new product that combines two of the firm’s top-selling drugs — its cholesterol drug Lipitor (atorvastatin calcium) and its high blood pressure drug Norvasc (amlodipine besylate).